Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16AX Various alimentary tract and metabolism products
A16AX20 Lonafarnib
D04768 Lonafarnib (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Lonafarnib
D04768 Lonafarnib (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D04768 Lonafarnib (JAN/USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
D04768 Lonafarnib
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
D04768 Lonafarnib
DG02852 CYP3A/CYP3A4 inhibitor
D04768 Lonafarnib
Transporter substrate
DG01665 ABCB1 substrate
D04768 Lonafarnib
Transporter inhibitor
DG01622 ABCB1 inhibitor
D04768 Lonafarnib
DG02864 SLC47A1 inhibitor
D04768 Lonafarnib
Target-based classification of drugs [BR:br08310]
Enzymes
Transferases (EC2)
Alkyl/Aryl transferases
FNT
D04768 Lonafarnib (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04768
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04768
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04768
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04768
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D04768
Drug transporters
D04768
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
D04768